Cryptococcosis diagnosis and treatment: What do we know now

被引:145
|
作者
Perfect, John R. [1 ]
Bicanic, Tihana [2 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[2] Univ London, Inst Infect & Immun, London, England
关键词
Medical mycology; Management; Meningitis; Pathophysiology; HIGH-DOSE FLUCONAZOLE; COURSE AMPHOTERICIN-B; HIV-INFECTED PATIENTS; INTRACRANIAL-PRESSURE; ANTIFUNGAL THERAPIES; FUNGAL BURDEN; LATERAL FLOW; MENINGITIS; NEOFORMANS; AIDS;
D O I
10.1016/j.fgb.2014.10.003
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epidemiology has been focused on three major outbreaks of disease that reflects both changing environmental exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have been bolstered by identification of the yeast's dynamic genomic structures and functions. It is during these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this infection with a new point-of-care, simple, cheap test which utilizes a lateral flow assay for antigen detection. With methods for effective identification of Cryptococcus in the host, the principles for management of this deadly infection include both use of old drugs and new insights into treatment strategies to improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to summarize our present knowledge base for this deadly fungal central nervous system infection with a particular emphasis on its diagnosis and management. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:49 / 54
页数:6
相关论文
共 50 条
  • [1] Treatment as prevention trials and ending AIDS: what do we know, when did we know it, and what do we do now?
    Granich, Reuben
    Williams, Brian G.
    CURRENT OPINION IN HIV AND AIDS, 2019, 14 (06) : 514 - 520
  • [2] HYPERSEXUALITY: WHAT DO WE KNOW BY NOW?
    Azevedo, P. A.
    Ferreira Carvalho, R. F. C.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S392 - S393
  • [3] TREATMENT WITH AN ULTRARAPID INHALED INSULIN - WHAT DO WE KNOW NOW?
    Boss, A. H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 : A12 - A13
  • [4] The epidemiology, diagnosis and treatment of subarachnoid haemorrhage in Nigeria: what do we know and what do we need to know?
    Ogungbo, B
    Mendelow, AD
    Walker, R
    BRITISH JOURNAL OF NEUROSURGERY, 2004, 18 (04) : 362 - 366
  • [5] NOW THAT WE KNOW YOUTH, WHAT WILL WE DO ABOUT IT
    ESTY, JC
    PHI DELTA KAPPAN, 1976, 57 (06) : 418 - 419
  • [6] Swift-Certain-Fair What Do We Know Now, and What Do We Need to Know?
    Kleiman, Mark A. R.
    Criminology & Public Policy, 2016, 15 (04) : 1185 - 1193
  • [7] What do we know about retention now?
    Richardson, Lorna
    EDINBURGH LAW REVIEW, 2018, 22 (03) : 387 - 393
  • [8] Religion and democratisation: what do we now know?
    Haynes, Jeffrey
    JOURNAL OF RELIGIOUS AND POLITICAL PRACTICE, 2016, 2 (02) : 267 - 272
  • [9] Anthocyanins: What do we know until now?
    Giampieri, Francesca
    Cianciosi, Danila
    Alvarez-Suarez, Jose M.
    Quiles, Jose L.
    Forbes-Hernandez, Tamara Y.
    Navarro-Hortal, Maria D.
    Machi, Michele
    Pali Casanova, Ramon del Jesus
    Martinez Espinosa, Julio Cesar
    Chen, Xiumin
    Di Zhang
    Bai, Weibin
    Tian Lingmin
    Mezzetti, Bruno
    Battino, Maurizio
    Diaz, Yasmany Armas
    JOURNAL OF BERRY RESEARCH, 2023, 13 (01) : 1 - 6
  • [10] The Dawn of Mitophagy: What Do We Know by Now?
    Belousov, Dmitrii M.
    Mikhaylenko, Elizaveta, V
    Somasundaram, Siva G.
    Kirkland, Cecil E.
    Aliev, Gjumrakch
    CURRENT NEUROPHARMACOLOGY, 2021, 19 (02) : 170 - 192